Generic Name and Formulations:
Flibanserin 100mg; tabs.
Bausch Health Companies Inc.
Indications for ADDYI:
Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women and is not due to a coexisting medical or psychiatric condition, problems within the relationship, or adverse effect of a medication or other drug substance.
Limitations Of use:
Not for HSDD in postmenopausal women or men. Not for sexual performance enhancement.
100mg daily at bedtime. Discontinue if no improvement after 8 weeks.
Concomitant alcohol, moderate or strong CYP3A4 inhibitors (eg, azole antifungals, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin, conivaptan, amprenavir, atazanavir, ciprofloxacin, diltiazem, erythromycin, fosamprenavir, verapamil, grapefruit juice). Hepatic impairment.
Hypotension. Syncope in certain settings.
Increased risk of severe hypotension and syncope with concomitant alcohol use. Assess patient's likelihood of alcohol abstinence prior to prescribing. Increased risk of CNS depression if taken during waking hours. Conditions that predispose to hypotension. CYP2C19 poor metabolizers; monitor. Pregnancy. Nursing mothers: not recommended.
5-HT1A agonist/5-HT2A antagonist.
See Contraindications. Increased risk of hypotension and syncope with concomitant moderate or strong CYP3A4 inhibitors, if use necessary, discontinue Addyi at least 2 days before starting the CYP3A4 inhibitor; discontinue the CYP3A4 inhibitor for 2 weeks before restarting Addyi. Increased risk of CNS depression with alcohol, other CNS depressants (eg, diphenhydramine, opioids, hypnotics, benzodiazepines), or strong CYP2C19 inhibitors (eg, PPIs, SSRIs, antifungals). Potentiated by weak CYP3A4 inhibitors (eg, oral contraceptives cimetidine, fluoxetine, ginkgo, resveratrol, ranitidine). Antagonized by CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St. Johns wort): not recommended. Potentiates digoxin, sirolimus, other P-gp substrates: monitor levels.
Dizziness, somnolence, nausea, fatigue, insomnia, dry mouth; hypotension, syncope.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds